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RESULTS: The strategy based on initial treatment with ﬂutica-
zone propionate nasal drops resulted with treatment cost of PLN
768, while early polypectomy resulted with cost of PLN 1251.
When surgery was performed in outpatients’ settings the mean
treatment costs were PLN 586 for initial ﬂuticazone and PLN
751 for early polypectomy. Sensitivity analysis revealed that
FPND is less costly therapy unless no computed tomography is
performed prior to polypectomy and the cost of surgical proce-
dure falls below PLN 170. CONCLUSIONS: Treatment strategy
based on ﬂuticasone propionate nasal drops is effective in bilat-
eral nasal polyposis and results in short-term cost savings.
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OBJECTIVES: To assess the clinical effectiveness and economic
consequences of telithromycin or clarithromycin in CAP treat-
ment from public payer perspective in Poland. METHODS:
Results of a systematic review of published clinical trials selected
in accordance with EBM criteria were used to assess effective-
ness and safety of the antibiotics in CAP treatment. The eco-
nomic consequences for public payer for therapy of individual
patient in case of clarithromycin replacement by Ketek
(telithromycin) were calculated. In this analysis it was assumed
that only pharmacotherapy costs and CAP hospitalization costs
differed; other costs were assumed to be the same irrelevant to
the antibiotic used. An assumption was made that level of phar-
macotherapy reimbursement in case of treatment with both
telithromycin and clarithromycin would be the same, public
payer costs for DDD were calculated. Costs of CAP hospitaliza-
tion varied on number of admissions during 1 month of follow-
up period. RESULTS: Clinical effects of the two drugs were
similar and no signiﬁcant differences in effectiveness or safety
were found in pooled data from two randomized clinical trials.
Telithromycin treatment was associated with signiﬁcantly fewer
CAP-related hospitalizations compared with clarithromycin
(1.6% vs 3.6% patients admitted, respectively). CAP-related
hospital costs per patient were much lower for telithromycin
treatment compared with clarithromycin (35.5pln (8.45E) vs.
79.2pln (18.8E) respectively). Taking into account reimburse-
ment of pharmacotherapy and costs of hospitalization, public
payer savings when using telithromycin in place of claritromycin
could be as high as 33pln(7.8E) - 50pln(12E)/patient (based on
sensitivity analysis). This lead to high annual savings for public
payer. CONCLUSIONS: Ketek (telithromycin) in place of clar-
ithromycin lead to signiﬁcant savings for public payer in CAP
treatment in Poland.
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OBJECTIVE: This study aimed to project future costs of asthma
and chronic obstructive pulmonary disease (COPD) in The
Netherlands for the period 2000–2025. METHODS: Gender-,
age- and (for COPD) disease-stage speciﬁc data on direct,
medical costs per patient were obtained from a cost of illness
study for the year 2000. Cost projections over the period
2000–2025 were based on two types of projections of the preva-
lence of asthma and COPD. Both prevalence projections were
combined with two types of cost projections; ﬁrst assuming con-
stant costs per patient and second adding asthma and COPD-
speciﬁc trends in costs for hospital care (asthma, -4.7% and
COPD, -4.1% per year) and medication (+4.9% per year) and
general trends in remaining cost categories. RESULTS: In 2000
the annual costs per asthma patient were €315, compared to
€915 for a COPD patient. Assuming constant costs per patient,
costs were projected to increase from €141 million in 2000 to
amounts between 167 and €181 million for asthma and from
280 to €443–495 million for COPD. Severity stage speciﬁc
COPD costs increased from 22.6 to 51.2 for mild COPD, from
104 to 148 for moderate, from 99.0 to 140 for severe and from
54.5 to €156 million for very severe COPD. Including trends
costs categories resulted in estimates between 460 and 497 for
asthma and 1023 and €1130 million for COPD. CONCLU-
SION: Projections of future costs show that the absolute and rel-
ative increase in costs over the period 2000–2025 is higher for
COPD than for asthma.
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OBJECTIVES: To assess the cost of managing COPD (health
care payers perspective) in a real life setting in Belgium.
METHODS: A multi-centre observational study with data-
collection in a retrospective way (one-year) was performed. A
total of 38GPs and 15pneumologists participated. Patients con-
sulting the physicians in Q4 2004–Q1 2005 were eligible. Indi-
vidual data-collection sheets per patient, evaluating the yearly
medical resource use, were completed by each investigator. Diag-
nostic methods, COPD severity, as well as smoking habits were
evaluated. RESULTS: A total of 460 patients were evaluated.
Mean age was 66 years, males represented 68.70%. 40.43% of
patients were smokers (average n pack-years 36.69, StErr 1.54),
50.22% ex-smokers. COPD diagnosis was made in about half
of the patients by both clinical evaluation and spirometry. A total
of 13% of the patients had mild COPD, 47% moderate, 30%
severe and 10% very severe COPD according to clinical evalua-
tion or spirometry (GOLD-guidelines). A total of 73% of the
patients experienced at least 1 exacerbation during the 1-year-
study-period. Yearly number of exacerbations ranged between 0
and 12 (average n: 1.37, median: 1.00). In most cases (69.64%),
no hospitalisation was needed. If hospitalized, average hospital
stay per exacerbation was 13.30 days (StErr 1.03). Yearly
COPD-maintenance-treatment cost ranged between 390€ (mild)
to €1117 (very severe COPD). Maintenance-treatment included
a wide range of medications. Management of COPD resulted in
a total yearly cost of €1810 (StErr 139.55, range €537 (mild
COPD)—€5888 (very severe COPD)), including maintenance-
treatment (€670, StErr 26.67), hospitalisation (€1073, StErr
130.16) and treatment of exacerbations (€67, StErr 6.78). CON-
CLUSIONS: Management of COPD is costly, mainly due to the
cost of hospitalisations. For very severe COPD patients, yearly
management costs increase up to almost €6000.
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